Pacific Biosciences (PACB) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Pacific Biosciences (PACB) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.2 per share a year ago.
Stay Ahead of the Game With Pacific Biosciences (PACB) Q2 Earnings: Wall Street's Insights on Key Metrics
Beyond analysts' top-and-bottom-line estimates for Pacific Biosciences (PACB), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Pacific Biosciences of California (PACB) Suffers a Larger Drop Than the General Market: Key Insights
Pacific Biosciences of California (PACB) reached $1.54 at the closing of the latest trading day, reflecting a -6.1% change compared to its last close.
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know
The latest trading day saw Pacific Biosciences of California (PACB) settling at $1.5, representing a +1.35% change from its previous close.
Here's Why You Should Add PacBio Stock to Your Portfolio Now
PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset macroeconomic concerns and drive 2025 growth.
Pacific Biosciences (PACB) Upgraded to Strong Buy: Here's What You Should Know
Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Pacific Biosciences of California (PACB) Outperforms Broader Market: What You Need to Know
Pacific Biosciences of California (PACB) closed at $1.18 in the latest trading session, marking a +1.72% move from the prior day.
Here's Why You Should Add PacBio Stock to Your Portfolio Now
PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset sales cycle delays and drive 2025 growth.
All You Need to Know About Pacific Biosciences (PACB) Rating Upgrade to Buy
Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PacBio Stock Slips Despite New China Distribution Deal With Haorui
PACB expands reach in China through Haorui Gene partnership, bringing HiFi sequencing to new clinical labs and boosting precision medicine access nationwide.
PACB Stock May Rise Following the Deal With Chulalongkorn University
PacBio and Chulalongkorn University launch Asia Pacific's first population-scale HiFi WGS newborn screening program, advancing precision medicine in Thailand.
